|
|
Phase III Randomized Study of Adjuvant Tamoxifen Versus Anastrozole in Postmenopausal Women With Ductal Carcinoma In Situ
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
40 to 70
|
|
|
|
Other
|
|
|
|
CRUK-IBIS-II-DCIS EU-20226, BIG-5-02, NCT00072462, IBCSG-31-03-DCIS, ISRCTN31488319
|
|
|
Objectives Primary - Compare the efficacy of adjuvant tamoxifen vs anastrozole, in terms of local control and prevention of contralateral disease, in postmenopausal women with locally excised ductal carcinoma in situ.
- Compare side effect profiles of these drugs in these patients.
Secondary - Compare the efficacy of these drugs, according to the receptor status of the primary or recurrent cancer in these patients.
- Compare the rate of breast cancer recurrence and growth of new contralateral tumors after cessation of treatment with these drugs in these patients.
- Compare breast cancer mortality in patients treated with these drugs.
- Compare the effect of these drugs on other cancers, cardiovascular disease, fracture rates, and non-breast cancer deaths in these patients.
- Compare the tolerability and acceptability of side effects experienced by patients treated with these drugs.
Entry Criteria Disease Characteristics:
- Diagnosis of ductal carcinoma in situ within the past 6 months
- Locally excised with tumor-free margins at least 1 mm
- Hormone receptor status:
- Estrogen or progesterone receptor positive
- Greater than 5% positive cells
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy Endocrine therapy - No prior or concurrent tamoxifen use lasting more than 3 months unless treatment was completed more than 5 years ago
- No prior or concurrent raloxifene use lasting more than 3 months unless treatment was completed more than 5 years ago
- No other prior or concurrent selective estrogen-receptor modulator use lasting more than 3 months unless treatment was completed more than 5 years ago
- No concurrent systemic estrogen-based hormone replacement therapy, including vaginal estrogen preparations
Radiotherapy Surgery - See Disease Characteristics
- No prior mastectomy
- No planned prophylactic mastectomy
Other - At least 3 months since prior unapproved or experimental agents
- No concurrent anticoagulants
Patient Characteristics:
Age Sex Menopausal status - Postmenopausal, defined as meeting at least 1 of the following criteria:
- Over age 60
- Prior bilateral oophorectomy
- Age 60 or under with a uterus AND amenorrhea for at least the past 12 months
- Age 60 or under without a uterus AND follicle-stimulating hormone greater than 20 IU/L
Performance status Life expectancy Hematopoietic Hepatic Renal Cardiovascular - No prior deep vein thrombosis
- No prior transient ischemic attack
- No prior cerebrovascular accident
Pulmonary - No prior pulmonary embolism
Other - No unexplained postmenopausal bleeding
- No other cancer within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results
- No evidence of osteoporosis
- Fragility fractures within the spine allowed if T-score level is greater than -4 and consist of no more than 2 fractures
- Psychologically and physically suitable for 5 years of study therapy
Expected Enrollment 4000A total of 4,000 patients will be accrued for this study within 4 years. Outcomes Primary Outcome(s)Development of histologically confirmed breast cancer, both invasive and non-invasive with median follow-up at 5 years
Secondary Outcome(s)Breast cancer mortality with median follow-up at 10 years
Outline This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral tamoxifen and oral placebo once daily.
- Arm II: Patients receive oral anastrozole and oral placebo once daily.
In both arms, treatment continues for 5 years in the absence of disease recurrence or unacceptable toxicity. Patients are followed annually for 5 years. Peer Reviewed and Funded or Endorsed by Cancer Research UK
Trial Contact Information
Trial Lead Organizations Cancer Research UK at Imperial College School of Medicine - London | | | Jack Cuzick, PhD, Study coordinator | | | |
International Breast Cancer Study Group | | | Katharina Buser, MD, Protocol chair | | | | Trial Sites
|
|
|
|
France |
|
|
Avignon |
|
| | | Institut Sainte Catherine |
| | Daniel Serin, MD | |
| Email:
d.serin@isc84.org |
|
|
Bordeaux |
|
| | Clinique Tivoli |
| | Dominique Jaubert, MD | |
| Email:
dominique.jaubert@wanadoo.fr |
| | Institut Bergonie |
| | Christine Tunon-de-Lara, MD | |
| Email:
tunon@bergonie.org |
| | Polyclinique Bordeaux Nord Aquitaine |
| | Nadine Dohollor | |
|
|
Brest |
|
| | CHU Hopital A. Morvan |
| | Helene Simon-Swirsky, MD | |
|
|
Caen |
|
| | Centre Regional Francois Baclesse |
| | Thierry Delozier, MD | |
| Email:
t.delozier@baclesse.fr |
|
|
Clermont-Ferrand |
|
| | Centre Jean Perrin |
| | Herve Cure, MD, PhD | |
|
|
Dijon |
|
| | Centre de Lutte Contre le Cancer Georges-Francois Leclerc |
| | Jean Cuisenier, MD | |
| Email:
jcuisenier@dijon.fnclcc.fr |
|
|
La Roche Sur Yon |
|
| | Centre Hospitalier Departemental |
| | Mohamad-Ayman Zawadi, MD | |
|
|
Lagny Sur Marne |
|
| | Centre Hospitalier de Lagny |
| | Daniele Chevallier | |
|
|
Le Havre |
|
| | CMC Les Ormeaux |
| | Gilles Piot, MD | |
|
|
Lille |
|
| | Centre Oscar Lambret |
| | Sylvia Giard-Lefevre, MD | |
| Email:
s-giard@o-lambret.fr |
|
|
Limoges |
|
| | Centre Hospital Regional Universitaire de Limoges |
| | Nicole Tubiana-Mathieu, MD | |
| Email:
oncologie@chu-limoges.fr |
|
|
Mulhouse |
|
| | Centre Hospitalier de Mulhouse |
| | Magali Edel, MD | |
|
|
Nantes-Saint Herblain |
|
| | Centre Regional Rene Gauducheau |
| | Dominique Berton-Rigaud, MD | |
|
|
Perpignan |
|
| | Clinique Saint - Pierre |
| | Pierre Castera | |
|
|
Reims |
|
| | Institut Jean Godinot |
| | Christiane Porrny | |
|
|
Rennes |
|
| | Centre Eugene Marquis |
| | Pierre Kerbrat, MD, PhD | |
| Email:
kerbrat@rennes.fnclcc.fr |
|
|
Rouen |
|
| | Centre Henri Becquerel |
| | Jean-Marie Ladonne | |
|
|
Toulouse |
|
| | Institut Claudius Regaud |
| | Laurence Gladieff, MD | |
| Email:
gladieff@icr.fnclcc.fr |
|
|
Villejuif |
|
| | Institut Gustave Roussy |
| | Suzette Delaloge | |
|
Switzerland |
|
|
Bern |
|
| | | Inselspital Bern |
| | Manuela Rabaglio, MD | |
| Email:
manuela.rabaglio@insel.ch |
| | Oncocare Sonnenhof-Klinik Engeriedspital |
| | Katharina Buser, MD | |
| Email:
kbuser@sonnenhof.ch |
|
|
Geneva |
|
| | Hopital Cantonal Universitaire de Geneve |
| | Pierre Chappuis, MD | |
| Email:
pierre.chappuis@hcuge.ch |
|
|
Lausanne |
|
| | Centre Hospitalier Universitaire Vaudois |
| | Contact Person | |
|
|
Mendrisio |
|
| | Ospedale Beata Vergine |
| | Olivia Pagani, MD | |
|
|
St. Gallen |
|
| | Tumor Zentrum ZeTup St. Gallen und Chur |
| | Senn Hans-Joerg, MD | |
| Email:
hjsenn@sg.zetup.ch |
|
|
Thun |
|
| | Regionalspital |
| | Daniel Rauch | |
|
United Kingdom |
|
England |
|
|
Birmingham |
|
| | | | City Hospital - Birmingham |
| | Jenny Williamson | |
|
|
Bristol |
|
| | Frenchay Hospital |
| | Simon Cawthorn, FRCS | |
|
|
Broomfield |
|
| | Broomfield Hospital |
| | Paul Sauven, MD, MS, FRCS | |
| Email:
paul.saauven@meht.nhs.uk |
|
|
Colchester |
|
| | Colchester General Hospital |
| | Fiona Macneill | |
|
|
Leeds |
|
| | Leeds Cancer Centre at St. James's University Hospital |
| | Mark Lansdown | |
| Email:
mark.lansdown@leedsth.nhs.uk |
|
|
Liverpool |
|
| | Royal Liverpool University Hospital |
| | Chris Holcombe | |
|
|
London |
|
| | Cancer Research UK |
| | Jack Cuzick, PhD | |
| | St. Thomas' Hospital |
| | Hisham Hamed, FRCS, PhD, MBBCh | Ph: | 44-207-188-4245 ext. 81467 | | |
|
| Email:
hisham.hamed@cancer.org.uk |
| | Whittington Hospital |
| | Richard Sainsbury, MD | |
|
|
Manchester |
|
| | Christie Hospital |
| | Anthony Howell, MD | |
| Email:
maria.parker@christie-tr.nwest.nhs.uk |
|
|
Newcastle-Upon-Tyne |
|
| | Newcastle Upon Tyne Hospitals NHS Trust |
| | Tom Lennard | |
| Email:
t.w.j.lennard@ncl.ac.uk |
|
|
Nottingham |
|
| | Nottingham City Hospital NHS Trust |
| | John Robertson | |
|
|
Southampton |
|
| | Royal South Hants Hospital |
| | Contact person | |
|
Northern Ireland |
|
|
Belfast |
|
| | | Centre for Cancer Research and Cell Biology at Queen's University Belfast |
| | Alan Wilkinson | |
|
Scotland |
|
|
Dundee |
|
| | | Ninewells Hospital |
| | Alistair M. Thompson | |
|
|
Edinburgh |
|
| | Royal Infirmary of Edinburgh at Little France |
| | Elaine Anderson | |
|
|
Glasgow |
|
| | Western Infirmary |
| | W. George | |
|
Wales |
|
|
Cardiff |
|
| | | University Hospital of Wales |
| | Robert Mansel | |
| Email:
manselre@cf.ac.uk |
|
Registry Information | | Official Title | | An International Multi-Centre Study Of Tamoxifen Vs Anastrozole In Postmenopausal Women With Ductal Carcinoma In Situ (DCIS) | | Trial Start Date | | 2003-09-25 | | Registered in ClinicalTrials.gov | | NCT00072462 | | Date Submitted to PDQ | | 2003-10-02 | | Information Last Verified | | 2007-07-03 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|